ESTRO 2024 - Abstract Book

S1834

Clinical - Mixed sites, palliation

ESTRO 2024

joints undergoing a first surgery and receiving PORT, recurrence occurred in 2/5 joints (40%). In joints undergoing a first surgery with either fasciectomy or needle aponeurotomy, there were no recurrences 0/3 (0%).

Conclusion:

These data suggest that in joints with prior surgeries, PORT is not effective. PORT may be of benefit if given after a first surgery with fasciectomy or needle aponeurotomy, though this trend was not observed after a first collagenase injection. As with any retrospective review, our study may be biased. This cohort may have been composed of patients who were more likely to develop a recurrence, as the majority of patients had multiple prior recurrences. This would decrease the perceived effectiveness of PORT. A clinical trial underway by the Australia New Zealand Clinical Trials Group is prospectively randomizing post-operative patients to either observation or PORT. This trial will provide further data to guide post- operative management of patients with Dupuytren’s contracture.

Keywords: Dupuytren's, Fibromatosis

147

Poster Discussion

Characteristics & quality of life in short and long survivors after radiotherapy for bone metastases

Renée Hovenier 1 , Eline H. Huele 1 , Bas J.J. Bindels 2 , Anouk van Oss 1,3 , Nicolien Kasperts 1 , Wietse S.C. Eppinga 1 , Yvette M. van der Linden 3 , Roxanne Gal 1 , Jorrit-Jan Verlaan 1 , Joanne M. van der Velden 1 , Helena M. Verkooijen 1 1 University Medical Center Utrecht, Division Imaging and Oncology, Utrecht, Netherlands. 2 University Medical Center Utrecht, Department of Orthopedic Surgery, Utrecht, Netherlands. 3 University Medical Center Leiden, Department of Radiotherapy, Leiden, Netherlands

Purpose/Objective:

Bone metastases are a substantial challenge in cancer management, often leading to pain, and reduced quality of life (QoL). External beam radiotherapy (EBRT) is proven to be highly effective in relieving symptoms and improving QoL outcomes for patients with symptomatic bone metastases. The median survival of patients with metastatic bone disease is typically 8 months, but some patients benefit from advancements in systemic treatments and radiotherapy strategies, substantially increasing their survival. This study evaluates characteristics and patient reported outcomes (PROs) of patients with short, moderate, and long-term survival up to 24 months after radiotherapy for bone metastases.

Material/Methods:

All patients with bone metastases enrolled in the prospective PRESENT cohort at the University Medical Center Utrecht (UMCU) between June 2013 and October 2021 were included. Based on their survival, patients were divided